Rise in US FDA approvals may signal an upsurge in biotech investments

<img width="250" height="167" src="https://www.leaprate.com/wp-content/uploads/2024/01/FIN-LP-Rise-in-US-FDA-approvals-may-signal-an-upsurge-in-biotech-investments-5777733813-iStock-1186545957-250×167.jpg" class="webfeedsFeaturedVisual wp-post-image" alt="" decoding="async" style="float: left; margin-right: 5px;" link_thumbnail="" srcset="https://www.leaprate.com/wp-content/uploads/2024/01/FIN-LP-Rise-in-US-FDA-approvals-may-signal-an-upsurge-in-biotech-investments-5777733813-iStock-1186545957-250×167.jpg 250w, https://www.leaprate.com/wp-content/uploads/2024/01/FIN-LP-Rise-in-US-FDA-approvals-may-signal-an-upsurge-in-biotech-investments-5777733813-iStock-1186545957-700×467.jpg 700w, https://www.leaprate.com/wp-content/uploads/2024/01/FIN-LP-Rise-in-US-FDA-approvals-may-signal-an-upsurge-in-biotech-investments-5777733813-iStock-1186545957-768×512.jpg 768w, https://www.leaprate.com/wp-content/uploads/2024/01/FIN-LP-Rise-in-US-FDA-approvals-may-signal-an-upsurge-in-biotech-investments-5777733813-iStock-1186545957-120×80.jpg 120w, https://www.leaprate.com/wp-content/uploads/2024/01/FIN-LP-Rise-in-US-FDA-approvals-may-signal-an-upsurge-in-biotech-investments-5777733813-iStock-1186545957-245×163.jpg 245w, https://www.leaprate.com/wp-content/uploads/2024/01/FIN-LP-Rise-in-US-FDA-approvals-may-signal-an-upsurge-in-biotech-investments-5777733813-iStock-1186545957-500×333.jpg 500w, https://www.leaprate.com/wp-content/uploads/2024/01/FIN-LP-Rise-in-US-FDA-approvals-may-signal-an-upsurge-in-biotech-investments-5777733813-iStock-1186545957.jpg 1254w" sizes="(max-width: 250px) 100vw, 250px" /><p>Some prominent therapeutics were featured in the 2023-approval batch. These included Zepbound, an obesity treatment developed by Eli Lilly and Company (LLY), and Leqembi, an Alzheimer&#8217;s drug from Eisai (ESAYI) and Biogen Inc. (BIIB).</p>
<p>On top of the 55 novel drug green lights, the FDA also put its stamp of approval on five gene therapies. One of these is a Vertex Pharmaceuticals Incorporated (VRTX) and CRISPR Therapeutics (CRSP) sickle cell disease treatment using gene editing innovations.</p>
<hr />
<p><a href="https://finaffiliates.us20.list-manage.com/subscribe/post?u=e0dd4d77c259eb270712a4eeb&amp;id=fd200b8f75&amp;v_id=4291&amp;f_id=00946ce6f0" target="_blank" rel="noopener">Don’t miss out the latest news, subscribe to LeapRate’s newsletter</a></p>
<hr />
<p>Reuters indicated the positive reaction from financial circles about the rise in FDA approvals. The newsagent quoted John Stanford, executive director of Incubate, a life sciences investment group, who commented:</p>
<blockquote><p>It is good to see the FDA approvals go up. Our scientists can do a lot more, and from that perspective, we are excited about what’s coming down the pipeline, not just in 2024, but beyond that.</p></blockquote>
<p>The approved gene therapies especially tweaked interest investor interest. The FDA mentioned that the number of novel <a href="https://www.leaprate.com/live-market-news/astrazenecas-q3-financial-report-bodes-profit-growth/" target="_blank" rel="noopener">drug approvals</a> depends on many variables, such as developments in science and an understanding of diseases.</p>
<p>The post <a rel="nofollow" href="https://www.leaprate.com/news/rise-in-us-fda-approvals-may-signal-an-upsurge-in-biotech-investments/">Rise in US FDA approvals may signal an upsurge in biotech investments</a> appeared first on <a rel="nofollow" href="https://www.leaprate.com">LeapRate</a>.</p>